FDA to decide on TG Therapeutics' lymphoma drug early next y...

The FDA has accepted TG Therapeutics’ filing for its lymphoma drug umbralisib, which if approved could compete against a combination therapy from Bristol-Myers Squibb and Roche.

Incyte/Morphosys take on CAR-Ts with $198,000 per year antib...

Incyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope to provide a more convenient alternative to expensive and cumberso

Scopus Bio preps trials of gene-silencing immuno-oncology dr...

Scopus BioPharma has licensed a gene-silencing drug from California’s City of Hope hospital that is due to start clinical testing in lymphoma patients later this year.

AbbVie forges $3.9 billion oncology alliance with Genmab

AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed by epcoritamab, a bispecific antibody in development for non-Hodgk

NICE backs Celgene’s Revlimid for chemo-free lymphoma therap...

Epizyme eyes lucrative use for newly-launched Tazverik

US biotech Epizyme is gearing up for a potentially lucrative second indication for its Tazverik (tazemetostat), after the FDA agreed to a fast review in follicular lymphoma.